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a b s t r a c t
The aim of this study was to show a lower incidence of febrile episodes in multiple myeloma patients
receiving lenograstim vs. ﬁlgrastim after high-dose cyclophosphamide for stem cell mobilization.
Patients treated with cyclophosphamide were randomly assigned to receive ﬁlgrastim or lenograstim.
Primary endpoint was the incidence of febrile episodes.vailable online 4 December 2010
eywords:
ilgrastim
-CSF
enograstim
5.1% patients developed a febrile episode, 9.1% with ﬁlgrastim and 1.1% with lenograstim. Lenograstim
group presented a signiﬁcantly higher absolute CD34+ cell number compared with the ﬁlgrastim group
but no differences were detected for collection efﬁcacy.
The study demonstrated a lower incidence of febrile episodeswith lenograstim compared to ﬁlgrastim.obilization
eutropenia
. Introduction
In current clinical practice, dose-intensive chemotherapy fol-
owed by peripheral blood stem cell transplantation (PBSCT) is
ommon in the treatment of a variety of hematopoietic malig-
ancies [1]. In patients with multiple myeloma (MM), the single
r tandem administration of high-dose melphalan followed by
BSCT is a standard treatment regimen [2]. A major advance in the
ttempt to mobilize blood stem cells from the bone marrow into
eripheral blood was achieved by the use of G-CSF in combina-
ion with chemotherapeutic agents [3]. In MM patients, high-dose
yclophosphamide chemotherapy followed by G-CSF administra-
ion is awell-consolidated and efﬁcient therapy in themobilization
rocess [4,5].
Two different recombinant human (rHu) G-CSFs are commer-
ially available, one glycosylated (lenograstim) and the other
∗ Corresponding author at: Department of Oncology, Transplants and Advanced
echnologies, University of Pisa, Via Roma 67, Pisa 56100, Italy.
el.: +39 050 99 28 15; fax: +39 050 83 01 62.
E-mail address: orci@sssup.it (E. Orciuolo).
145-2126/© 2010 Elsevier Ltd. Open access under CC BY-NC-ND license.
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non-glycosylated (ﬁlgrastim). Despite this difference, the major-
ity of studies and clinical trials to date have not considered the
potential different effects that glycosylation may confer. In fact,
there is substantial evidence that glycosylation modiﬁes the chem-
ical properties of G-CSF, conferring a higher molecular stiffness,
pH, temperature and elastase resistance that translate to a higher
plasma half-life [6–8]. Additionally, glycosylation reduces the for-
mation of aggregates and increases receptor afﬁnity, causing an
increment in bioavailability and molecular activity [9,10]. Glycosy-
lation of G-CSF is also associated with additional biological effects.
For example, neutrophils exposed in vitro to non-glycosylated G-
CSF present reduced motility [11], morphological abnormalities
[12], increased spontaneous actin polymerization [13] and RhoA
activation [14], a more immature phenotype and a slight reduc-
tion in the release of reactive oxygen species (ROS) compared with
those exposed to glycosylated G-CSF [15]. All of these features con-
tribute to the impairment of both chemotaxis and the capability to
respond correctly to further stimulation [13,14]. Consistent with
theseﬁndings, neutrophils exposed tonon-glycosylatedG-CSFmay
be less effective in preventing febrile episodes (FE) in patients with
chemotherapy-derived neutropenia when compared with those
exposed to glycosylated G-CSF.
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Table 1
Patient characteristics.
Filgrastim
n = 88
Lenograstim
n = 88
All patients
n = 176
Age
[Median (range)] 60 (39–70) 57 (35–70) 59 (35–70)
Sex  N (%)
Female 42 (47.7) 40 (45.5) 82 (46.6)
Male  46 (52.3) 48 (54.5) 94 (53.4)
ECOG  N (%)
0 59 (67) 60 (68.2) 119 (67.6)
1 26  (29.5) 27 (30.7) 53 (30.1)
2  3 (3.4) 1 (1.1) 4 (2.3)
Disease stage N (%)
I 8 (9.1) 12 (13.6) 20 (11.4)
II  7 (8) 9 (10.2) 16 (9.1)
III 73 (83) 67 (76.1) 140 (79.5)
Previous chemotherapy N (%)
DAV 18 (20.5) 15 (17) 33 (18.8)
LENA 7 (8) 6 (6.8) 13 (7.4)
TD 40 (45.5) 34 (38.6) 74 (42)
VD  13 (14.8) 13 (14.8) 26 (14.8)
VTD  10 (11.4) 20 (22.7) 30 (17)
Cyclophosphamide dose (g/sqm) N (%)
2 1 (1.1) 0 (0) 1 (0.6)
3 31 (35.2) 32 (36.4) 63 (35.8)
4  44 (50) 46 (52.3) 90 (51.1)
5 9 (10.2) 7 (8) 16 (9.1)
7  3 (3.4) 3 (3.4) 6 (3.4)
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1Patients enrolled in the two study arms were not signiﬁcantly differen
stages), previous chemotherapy treatment and cyclophosphamide do
mide,  dexamethasone; TD: thalidomide, dexamethasone; VD: bortezo
The aim of this study was to evaluate the incidence of febrile
pisodes in patients treated with lenograstim in comparison with
atients treated with ﬁlgrastim after high-dose cyclophosphamide
n the context of peripheral blood stem cell mobilization and har-
est.
. Materials and methods
.1. Protocol approval
This was a randomized, prospective, multicentre, open-label, comparative
tudy. The study was  approved by the research ethics committee of the Univer-
ity of Pisa (Coordinating Center) and by the local ethics committees of each of the
1  participating centres. The study was conducted according to the principles of the
eclaration of Helsinki and Good Clinical Practice. All patients signed a form giving
heir fully informed consent to participate in the study. The study is registered at
linicalTrials.gov, number NCT00932217.
.2. Study population
Patients aged 18–70 years with a diagnosis of MM and who were sched-
led to receive high-dose chemotherapy were eligible. The criteria for inclusion
ere performance status grade ≤2 according to the Eastern Cooperative Oncol-
gy  Group (ECOG), neutrophil count >1500/mcL, platelet count >100,000/mcL,
emoglobin >10 g/dL, normal hepatic function (<1.5 × upper limit of normal), cre-
tinine < 2 × upper limit of normal, cardiac function normal for the age, HCV and
bsAg negativity, interval between previous induction chemotherapy and high dose
yclophosphamide chemotherapy of 30–60 days. Exclusion criteria were severe
ardiac dysfunction, uncontrolled concomitant morbidities, and suspected or doc-
mented infections.
.3. Treatment
Eligible patients were randomized to receive either lenograstim or ﬁlgrastim
n  a 1:1 ratio, according to a randomization list generated using a standard per-
uted block of four without stratiﬁcation. The list was generated using the SAS Plan
rocedure version 8.2.
All patients received a high-dose chemotherapy regimen of cyclophosphamide
2–7 g/sqm according to the routine practice of each participating centre) on day 1 of
he study. Administration of the assigned rHu G-CSF started on day 4 until day 7 at a
osage of 30 MU/day, which was increased to 60 MU/day from day 8 until the end of
phaeresis. Aphaeresis was  initiated when at least 10 ×106/L of CD34+ cells/kgbw
ere present. Aphaeresis was  repeated if necessary on consecutive days (until day
5) to obtain at least 6 × 106 CD34+ cells/kgbw. Between days 15 and 20 patientserms of age, sex, ECOG, disease stage (according to Durie and Salmon
eived. DAV: dexamethasone, adriamycin, vincristine; LENA: lenalido-
examethasone; VTD: bortezomib, thalidomide, dexamethasone.
underwent to the end of treatment visit and on day 30 to the end of study visit.
Concomitant anti-infective prophylaxis with antibiotics, antimycotic and antiviral
drugs were allowed at the physician’s discretion. Other concomitant drugs could
also be used but had to be reported.
2.4. Study endpoints
2.4.1. Primary endpoint
The primary endpoint of the study was the incidence of febrile episodes
after rHu G-CSF administration following high-dose chemotherapy. All patients
were expected to experience grade 4 neutropenia as a consequence of high-dose
chemotherapy. Febrile episodes occurring during grade 4 neutropenia were not
included in the incidence rate because they would not be inﬂuenced by the effect
of G-CSF on neutrophil function, but were reported as adverse events. The period of
recovery from neutropenia, as an effect of rHu G-CSF administration, started when
the  neutrophil count was above 500/mcL.
Febrile episodes were recorded from the ﬁrst rHu G-CSF administration to day
30, excluding the period of grade 4 neutropenia, and were considered signiﬁcant
when temperature was ≥38 ◦C for at least 2 different measurements.
2.4.2. Secondary endpoints
Secondary endpoints of the study were differences between the two rHu  G-
CSFs in terms of mobilization efﬁcacy, collection efﬁcacy, the number of aphaereses
needed to obtain the threshold number of 6 × 106 CD34+ cells/kgbw and time to
rich  the threshold number of CD + 34 cells.
Mobilization efﬁcacy has been deﬁned as the absolute number of CD34+ cells
in  the bloodstream after 6–9 days from the beginning of growth factor therapy.
Collection efﬁcacy has been deﬁned as the number of patients that achieved the
threshold of 6 × 106 CD34+ cells/kgbw.
In  the absence of fever, patients were admitted as outpatients for stem cell
aphaeresis. Successful leukapheresis was deﬁned as a procedure giving the threshold
number of 6 × 106 CD34+ cells/kgbw.
Adverse events occurring during the 30-day study period were reported accord-
ing  to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. In patients
developing febrile episodes, blood and urine were analyzed microbiologically and
chest X-ray was performed. According to clinical symptoms, a mucosa smear or a
stool sample was  also analyzed microbiologically.
2.5. Statistical analysesA total sample size of 180 patients randomized in a 1:1 ratio was calculated
to  achieve a power close to 80% to detect a difference in the proportion of patients
with febrile episodes between groups of 12%. The proportion of patients with febrile
episodes in the control group (ﬁlgrastim) was assumed to be 15% while the propor-
tion  in the test group (lenograstim) was predicted to be 3%, according to the results
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ﬁig. 1. Consort diagram: 180 patients were enrolled in the study. 176 patients
eceived study drugs, 88 patients in each study arm. AE: adverse event.
f  a retrospective analysis conducted at the University of Pisa (unpublished data).
he statistical test used was the two-sided Fisher’s Exact test. The signiﬁcance level
f  the test was  targeted at 0.05.
All randomized patients who received at least one dose of the study medi-
ation were included in the efﬁcacy and safety analyses. The demographic and
linical–pathological characteristics were summarized by means of descriptive
tatistics.
In  general, absolute and relative frequencies were employed to summarize qual-
tative variables while arithmetic mean, standard deviation (SD), range and median
ere used to summarize quantitative data.
Comparisons between treatments were tested using one-way analysis of vari-
nce (ANOVA) for continuous variables and chi-square test or Fisher’s exact test, if
eemed more appropriate (primary endpoint analysis), for categorical data. Due to
he  supportive and exploratory nature of the secondary endpoints, no adjustments
or  multiplicity were performed for the multiple comparisons across days. Differ-
nces were considered as statistically signiﬁcant for two-tailed p-values ≤0.05. All
tatistical computations were performed using the SAS system version 9.1.3.
. Results
.1. Patient characteristics and treatments
Between April 2005 and July 2009, 180 patients diagnosed with
M who were admitted to 11 Italian Hematology Centers for mobi-
ization chemotherapy were enrolled into the clinical trial. The
aseline characteristics of the patients are summarized in Table 1.
he two groups of patients were comparable in terms of age,
ex, ECOG, disease stage, previous chemotherapy treatment and
yclophosphamide dose received. Among all randomized patients,
 patients did not receive the study drug and were not evaluable: 2
atients withdrew consent, 2 patients were not eligible for mobi-
ization due to the worsening of health conditions after high-dose
yclophosphamide therapy. Of the 176 evaluable patients, 88 were
andomly assigned to ﬁlgrastim and 88 to lenograstim treatment
Fig. 1).
Patients received high-dose cyclophosphamide on day 1, and
Hu G-CSF therapy from day 4. All 176 patients experienced grade
 neutropenia, as expected after high-dose cyclophosphamide ther-
py. 7 of 88 and 8 of 88 patients treated with lenograstim and
lgrastim, respectively, were not eligible for aphaeresis, because ofFig. 2. Incidence of febrile episodes: the cumulative number of febrile episodes in
the ﬁlgrastim and the lenograstim groups, after G-CSF administration on day 1.
fever during the period of grade 4 neutropenia. 81 and 80 patients
treated with lenograstim and ﬁlgrastim, respectively, were eligi-
ble for aphaeresis. In the lenograstim group, 9 patients did not
undergo aphaeresis, 3 due to unsuccessful placement of a central
line and 6 due to mobilization failure. In the ﬁlgrastim group, 4
patients did not undergo aphaeresis due to mobilization failure.
Consequently, 81.8% (72/88) of lenograstim- and 86.4% (76/88) of
ﬁlgrastim-treated patients underwent aphaeresis.
3.2. Incidence of febrile episodes
In the time-frame between the ﬁrst rHu G-CSF administration
and day 30, 9 of the 176 patients (5.1%) had a febrile episode,
including 9.1% (8/88) of the ﬁlgrastim group and 1.1% (1/88) of
the lenograstim group. This difference was  statistically signiﬁcant
(p = 0.03) (Fig. 2).
3.3. Mobilization efﬁcacy
Eighty-one patients in the lenograstim group and 80 in the ﬁl-
grastim group were evaluable for mobilization efﬁcacy. Six days
after the beginning of rHu G-CSF treatment, the lenograstim group
presented a signiﬁcantly higher absolute CD34+ cell number when
compared with the ﬁlgrastim group: 60.45 (±55.21) × 106 vs. 7.29
(±8.86) ×106 CD34+ cells, respectively (p = 0.0159). The absolute
count of CD34+ cells in the lenograstim group on days 7, 8 and 9
after rHu G-CSF treatment was  always higher than in the ﬁlgras-
tim group, but the difference between groups was  not statistically
signiﬁcant (Fig. 3).
3.4. Collection efﬁcacy
65.4% (53/81) of patients in the lenograstim and 65% (52/80) in
the ﬁlgrastim group reached the target cell dose harvest of 6 × 106
CD34+ cells/kgbw (p = ns) (Fig. 4). No difference was  found between
the two groups of patients in the total number of aphaereses needed
to obtain the target dose of CD34+ cells: 90 and 95 in the lenogras-
tim and in ﬁlgrastim groups, respectively. The median number of
days needed to reach the target threshold of CD34+ cells was  8
days (range 3–12) and 9 days (range 6–14) the for lenograstim and
ﬁlgrastim groups, respectively.
902 E. Orciuolo et al. / Leukemia Res
Fig. 3. Mobilization efﬁcacy: mean absolute count of CD34+ stem cells after 6–9
days  from the beginning of rHu G-CSF therapy.
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with that published in the literature by de Arriba et al. [17]. The lackig. 4. Collection efﬁcacy: percentage of patients who  reached the target cell dose
arvest of 6 ×106 CD34+ cells/kgbw. 73.6% (53/72) in the lenograstim and 68.4%
52/76) in the ﬁlgrastim group reached the target cell dose (p = ns) after G-CSF
dministration on day 1.
.5. Safety
In general, treatment with high-dose cyclophosphamide and
-Hu G-CSF (both lenograstim and ﬁlgrastim) was well tolerated.
verall, 10.8% (19/176) of patients experienced at least one adverse
vent (any grade), 12.5% (11/88) in the lenograstim and 9.1% (8/88)
n the ﬁlgrastim group (p = ns). Neutropenia was excluded, as well
s anaemia and thrombocytopenia not requiring therapy, because
hese events were expected as a direct consequence of high-dose
yclophosphamide treatment. Febrile episodes were considered
dverse events when occurring during the period of grade 4 neu-
ropenia, and accounted for 9 and 8 cases in the lenograstim and
lgrastim arms, respectively (p = ns). Overall, 14.8% (26/176) of
atients experienced fever, 11.4% (10/88) in the lenograstim arm
nd 18.2% (16/88) in the ﬁlgrastim arm. Additionally, no signiﬁcant
ifferences were evident between the two treatment groups with
egard to concomitant therapies. Antibiotic, antimycotic and antivi-
al prophylaxis was used in 53.4% (47/88), 33.0% (29/88) and 17.1%
15/88) of patients, respectively, in the lenograstim group vs. 58.0%
51/88), 36.4% (32/88) 19.3% (17/88), respectively, in the ﬁlgrastim
roup.. Discussion
This study showed a signiﬁcantly higher incidence of febrile
pisodes during neutropenia recovery in multiple myelomaearch 35 (2011) 899– 903
patients treated with ﬁlgrastim in comparison with those treated
with lenograstim. This is possibly related to an impairment of
the neutrophil activity when exposed to non-glycosylated G-CSF
[11–15]. Additional conﬁrmation of this hypothesis is provided by
the febrile episodes observed during grade 4 neutropenia: in the
absence of neutrophils the difference between the two formula-
tions is abrogated, with 9 and 8 cases recorded in the lenograstim
and ﬁlgrastim groups, respectively.
G-CSF, the primary regulator of granulopoiesis, has shown efﬁ-
cacy in reducing the duration of neutropenia after chemotherapy or
myelosuppressive therapy. In these situations G-CSF, by accelerat-
ing granulocyte reconstitution, may  enable a signiﬁcant reduction
in the incidence, duration and severity of infection [16].
rHu G-CSFs on the market include lenograstim, a glycosylated
form, and ﬁlgrastim, a non-glycosylated form. Glycosylation of the
molecule confers pharmacokinetic advantages and a higher afﬁn-
ity for speciﬁc receptors [10]. Additionally, lenograstim-exposed
neutrophils maintain all of their functions in vitro, while ﬁlgrastim-
exposed neutrophils present functional defects due to higher
adhesiveness, cytoskeletal alterations and a more immature phe-
notype [14]. Based on in vitro evidence, granulocytes primed with
non-glycosylated G-CSF show a lower functionality and a less
mature phenotype compared with those primed with glycosylated
G-CSF [15].
Multiple myeloma patients were chosen because of the highly
immunosuppressive drugs they receive as front-line therapy and
the standard mobilization process with high dose cyclophos-
phamide that ensures the development in all treated cases of grade
4 neutropenia.
It should be noted that only febrile episodes occurring from
the ﬁrst rHu G-CSF administration to day 30 were included in
the primary endpoint, as febrile episodes occurring prior to this
could not be related to differences between the glycosylated and
non-glycosylated compounds in preserving neutrophil function. In
addition, only febrile episodes occurring after neutropenia recov-
ery (absolute neutrophil count >500/mcL) were considered in the
primary endpoint; during grade 4 neutropenia the incidence of
febrile episodes was  unlikely to have been inﬂuenced by neutrophil
function given the low numbers of cells present.
Due to the low number of febrile episodes occurring in the
study, and the fact that only in a minority of cases the pathogens
responsible were identiﬁed, it was not possible to identify a pre-
dominant etiological agent for these infections. However, all the
documented cases were caused by bacterial infections. Impor-
tantly, the prophylactic use of antimicrobial therapy (antibiotic,
antimycotic and antiviral) was permitted during the study, with
similar proportions of patients in each study receiving treatment.
Interestingly, no differences were documented in patients receiv-
ing such prophylaxis compared with those that did not. Our  study
does not suggest a need for routine antimicrobial prophylaxis in
MM patients undergoing high dose cyclophosphamide therapy
with G-CSF administration, unless necessary given an individual
patient’s history of infection.
With regard to secondary endpoints, stem cell mobilization
seems to be much more effective with the use of lenograstim com-
pared with ﬁlgrastim, with stem cell mobilization occurring one
day earlier (day 6 after G-CSF administration) when lenograstim
was used. Additionally, there was a trend towards a higher abso-
lute count of mobilized stem cells after lenograstim administration
compared with ﬁlgrastim. In our study this difference was  statis-
tically signiﬁcant only on day 6, but the overall trend is consistentof a consistent statistically signiﬁcant effect may  be due to the small
number of patients included in our study, when compared with the
sample size of the previous study. Regarding collection efﬁciency,
our study did not demonstrate any signiﬁcant difference between
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for mobilization of PBPCs. Bone Marrow Transplant 2010;45(2):277–E. Orciuolo et al. / Leukem
lgrastim and lenograstim in the number of patients achieving the
arget dose of CD34+ cells, as well as in the total number of cells
ollected and in the number of necessary aphaeretic processes.
owever, previous reports have demonstrated such differences
n a larger sample size, and, most importantly, in monocentric
xperiences [18]. Our study, conducted in 11 haematology centres,
ncludes the important bias of different procedures applied at the
ifferent sites, which may  account for the apparent lack of differ-
nce between the two treatment arms. However, patients treated
ith lenograstim, also in our multicentre trial, appear to reach
he target dose of stem cells in a slightly shorter time, reducing
he duration of neutropenia, the risk of infection, and procedure-
ssociated costs [17]. Recently Hölig et al. evaluated the safety
nd mobilization efﬁcacy of G-CSF in 3928 healthy donors, most
f whom (97.3%) were treated with lenograstim. One leukaphere-
is was adequate to collect the target CD34+ cell dose in 78% of
he donors and the “mobilization failure” rate was as low as 0.45%
19]. Again, our multicentre experience did not reproduce such a
igh procedure success rate, however it conﬁrmed the safety and
easibility of stem cell mobilization in MM patients.
Finally, ﬁlgrastim and lenograstim presented a similar safety
roﬁle, with no signiﬁcant differences between the two  treatment
rms.
In conclusion, our study demonstrated a lower inci-
ence of febrile episodes in MM patients recovering from
yclophosphamide-induced grade 4 neutropenia when treated
ith lenograstim, indirectly conﬁrming a functional block on
eutrophil activity as a consequence of ﬁlgrastim exposure.
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